Iatrogenic lipodystrophy in HIV patients - the need for very-low-fat diets.
In HIV patients, chronic treatment with protease inhibitors often precipitates a peripheral lipodystrophy associated with insulin resistance syndrome and premature coronary disease. In vitro studies demonstrate that these drugs can compromise the ability of adipocytes to store triglycerides; in vivo, peripheral subcutaneous adipocytes appear to be most affected, such that body fat often redistributes to visceral or truncal adipose stores. Dysfunction of peripheral subcutaneous adipocytes - ordinarily quite efficient for storing fat - can be expected to give rise to an excessive flux of free fatty acids (FFAs) following fatty meals; chronic overexposure of tissues to FFAs is a likely explanation for the insulin resistance syndrome associated with lipodystrophy. These considerations suggest that a very-low-fat diet - less than 15% fat calories - may ameliorate the cardiovascular risk associated with lipodystrophy; such diets are known to have a favorable effect on the insulin sensitivity of healthy subjects. Very-low-fat whole-food vegan diets are particularly recommendable in this context, as they may help to shrink visceral fat depots while markedly reducing LDL cholesterol. Appropriate adjunctive measures may include aerobic exercise training - beneficial both for insulin sensitivity and weight control - as well as administration of statins or policosanol, and of fibrates or fish oil, to decrease LDL and triglycerides, respectively. Despite perceptions to the contrary, very-low-fat diets can meet with good compliance in well-motivated subjects given appropriate instruction.
Pantox Laboratories, San Diego, CA 92109, USA. mccarty@pantox.com
M F
MF
McCarty
D017667:Adipocytes / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D018752:Diet, Fat-Restricted; D014676:Diet, Vegetarian; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D007049:Iatrogenic Disease; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000209:etiology*; D008962:Models, Theoretical; D019518:Postprandial Period; D011480:Protease Inhibitors / Q000494:pharmacology
D008078:Cholesterol, LDL; D011480:Protease Inhibitors